SIRPA and glioblastoma: The augmentation of macrophage phagocytosis of tumor cells has been observed in various preclinical tumor models, such as small-cell lung cancer, anaplastic thyroid carcinoma, and glioblastoma, through the implementation of monoclonal antibodies or fusion proteins to obstruct the CD47/SIRPα axis [13–15].